Biophysical characterization of Abeta42 C-terminal fragments: inhibitors of Abeta42 neurotoxicity
- PMID: 20050679
- PMCID: PMC2831638
- DOI: 10.1021/bi902075h
Biophysical characterization of Abeta42 C-terminal fragments: inhibitors of Abeta42 neurotoxicity
Abstract
A key event in Alzheimer's disease (AD) is age-dependent, brain accumulation of amyloid beta-protein (Abeta) leading to Abeta self-association into neurotoxic oligomers. Previously, we showed that Abeta oligomerization and neurotoxicity could be inhibited by C-terminal fragments (CTFs) of Abeta42. Because these CTFs are highly hydrophobic, we asked if they themselves aggregated and, if so, what parameters regulated their aggregation. To answer these questions, we investigated the dependence of CTF aqueous solubility, aggregation kinetics, and morphology on peptide length and sequence and the correlation between these characteristics and inhibition of Abeta42-induced toxicity. We found that CTFs up to 8 residues long were soluble at concentrations >100 microM and had a low propensity to aggregate. Longer CTFs were soluble at approximately 1-80 microM, and most, but not all, readily formed beta-sheet-rich fibrils. Comparison to Abeta40-derived CTFs showed that the C-terminal dipeptide I41-A42 strongly promoted aggregation. Aggregation propensity correlated with the previously reported tendency to form beta-hairpin conformation but not with inhibition of Abeta42-induced neurotoxicity. The data enhance our understanding of the physical characteristics that affect CTF activity and advance our ability to design, synthesize, and test future generations of inhibitors.
Figures




Similar articles
-
A two-step strategy for structure-activity relationship studies of N-methylated aβ42 C-terminal fragments as aβ42 toxicity inhibitors.ChemMedChem. 2012 Mar 5;7(3):515-22. doi: 10.1002/cmdc.201100584. Epub 2012 Feb 3. ChemMedChem. 2012. PMID: 22307963 Free PMC article.
-
Mechanistic investigation of the inhibition of Abeta42 assembly and neurotoxicity by Abeta42 C-terminal fragments.Biochemistry. 2010 Aug 3;49(30):6358-64. doi: 10.1021/bi100773g. Biochemistry. 2010. PMID: 20568734 Free PMC article.
-
C-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicity.Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14175-80. doi: 10.1073/pnas.0807163105. Epub 2008 Sep 8. Proc Natl Acad Sci U S A. 2008. PMID: 18779585 Free PMC article.
-
Aβ42 and Aβ40: similarities and differences.J Pept Sci. 2015 Jul;21(7):522-9. doi: 10.1002/psc.2789. Epub 2015 May 28. J Pept Sci. 2015. PMID: 26018760 Review.
-
Protection mechanisms against Abeta42 aggregation.Curr Alzheimer Res. 2008 Dec;5(6):548-54. doi: 10.2174/156720508786898460. Curr Alzheimer Res. 2008. PMID: 19075581 Review.
Cited by
-
A two-step strategy for structure-activity relationship studies of N-methylated aβ42 C-terminal fragments as aβ42 toxicity inhibitors.ChemMedChem. 2012 Mar 5;7(3):515-22. doi: 10.1002/cmdc.201100584. Epub 2012 Feb 3. ChemMedChem. 2012. PMID: 22307963 Free PMC article.
-
Protein amyloids develop an intrinsic fluorescence signature during aggregation.Analyst. 2013 Apr 7;138(7):2156-62. doi: 10.1039/c3an36798c. Epub 2013 Feb 18. Analyst. 2013. PMID: 23420088 Free PMC article.
-
Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal models.Curr Pharm Des. 2014;20(15):2469-83. doi: 10.2174/13816128113199990496. Curr Pharm Des. 2014. PMID: 23859557 Free PMC article. Review.
-
Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease?Neuron. 2016 Sep 7;91(5):957-973. doi: 10.1016/j.neuron.2016.08.027. Neuron. 2016. PMID: 27608759 Free PMC article. Review.
-
Short Peptides as Inhibitors of Amyloid Aggregation.Open Biotechnol J. 2011 Dec 23;5:39-46. doi: 10.2174/1874070701105010039. Open Biotechnol J. 2011. PMID: 24653784 Free PMC article.
References
-
- Walsh DM, Selkoe DJ. Aβ oligomers - a decade of discovery. J. Neurochem. 2007;101:1172–1184. - PubMed
-
- Kirkitadze MD, Bitan G, Teplow DB. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. J. Neurosci.Res. 2002;69:567–577. - PubMed
-
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356. - PubMed
-
- Ferreira ST, Vieira MN, De Felice FG. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life. 2007;59:332–345. - PubMed
-
- Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-β protein assembly in the brain impairs memory. Nature. 2006;440:352–357. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources